Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
International Urology and Nephrology
Erschienen in:

08.08.2023 | Nephrology - Review

Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease

verfasst von: Xuexun Chen, Xuan Li, Bo Cao, Xinping Chen, Kexin Zhang, Fang Han, Chengxia Kan, Jingwen Zhang, Xiaodong Sun, Zhentao Guo

Erschienen in: International Urology and Nephrology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Diabetic kidney disease (DKD) is a serious complication of diabetes and is the primary cause of end-stage renal disease. Current treatment strategies primarily focus on the inhibition of the renin–angiotensin–aldosterone system and the attainment of blood glucose control. Although current medical therapies for DKD have been shown to delay disease progression and improve long-term outcomes, their efficacy is limited and they may be restricted in certain cases, particularly when hyperkalemia is present. Traditional Chinese medicine (TCM) treatment has emerged as a significant complementary approach for DKD. TCM monomers, derived from various Chinese herbs, have been found to modulate multiple therapeutic targets and exhibit a broad range of therapeutic effects in patients with DKD. This review aims to summarize the mechanisms of action of TCM monomers in the treatment of DKD, based on findings from clinical trials, as well as cell and animal studies. The results of these investigations demonstrate the potential effective use of TCM monomers in treating or preventing DKD, offering a promising new direction for future research in the field. By providing a comprehensive overview of the mechanisms and efficacy of TCM monomers in DKD, this review highlights the potential of these natural compounds as alternative therapeutic options for improving outcomes in patients with DKD.
Literatur
1.
Helou N et al (2016) Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis. JBI Database System Rev Implement Rep 14(7):169–207PubMedCrossRef
2.
Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ (2017) Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med 34(7):887–901PubMedCrossRef
3.
Ogurtsova K, da Rocha Fernandes JD, Huang Y et al (2017) IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50PubMedCrossRef
4.
Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22(Suppl 1):3–15PubMedCrossRef
5.
Piao Y, Yin D (2018) Mechanism underlying treatment of diabetic kidney disease using traditional Chinese medicine based on theory of Yin and Yang balance. J Tradit Chin Med 38(5):797–802PubMedCrossRef
6.
Lin YC, Chang YH, Yang SY, Wu KD, Chu TS (2018) Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 117(8):662–675PubMedCrossRef
7.
Lewis EJ (2002) The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 15(10 Pt 2):123S-128SPubMedCrossRef
8.
Rayner B (2004) Advances in the treatment of diabetic renal disease: focus on losartan. Curr Med Res Opin 20(3):333–340PubMedCrossRef
9.
10.
van der Sande NG et al (2016) Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes Obes Metab 18(11):1120–1127PubMedCrossRef
11.
Ma J et al (2013) Effects of zishentongluo in patients with early-stage diabetic nephropathy. Am J Chin Med 41(2):333–340PubMedCrossRef
12.
Shi R et al (2019) Efficacy of co-administration of Liuwei Dihuang Pills and Ginkgo biloba tablets on albuminuria in type 2 diabetes: a 24-month, multicenter, double-blind, placebo-controlled, Randomized clinical trial. Front Endocrinol (Lausanne) 10:100PubMedCrossRef
13.
Yang X et al (2016) Effects of Tangshen formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen formula in patients with type 2 diabetic kidney disease. BMC Complement Altern Med 16:246PubMedPubMedCentralCrossRef
14.
Coimbra TM, Janssen U, Gröne HJ et al (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57(1):167–182PubMedCrossRef
15.
Hassan Yankuzo QUA, Rahajoe Imam Santosa SFUA, Talib NA（2011）Beneficial effect of the leaves of Murraya koenigii (Linn.) Spreng (Rutaceae) on diabetes-induced renal damage in vivo. J Ethnopharmacol 135(1):88–94
16.
Meza Letelier CE et al (2017) Pathophysiology of diabetic nephropathy: a literature review. Medwave 17(1):e6839PubMedCrossRef
17.
Izquierdo-Lahuerta A, Martínez-García C, Medina-Gómez G (2016) Lipotoxicity as a trigger factor of renal disease. J Nephrol 29(5):603–610PubMedCrossRef
18.
Soetikno V et al (2013) Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats. J Nutr Biochem 24(5):796–802PubMedCrossRef
19.
Tsun JG, Yung S, Chau MK, Shiu SW, Chan TM, Tan KC (2014) Cellular cholesterol transport proteins in diabetic nephropathy. PLoS One 9(9):e105787PubMedPubMedCentralCrossRef
20.
21.
Dan Tang WH, Zhi-Tong Zhang JS, Xue Wang WG (2022) Protective effects of Huang-Lian-Jie-Du Decoction on diabetic nephropathy through regulating AGEs/RAGE/Akt/Nrf2 pathway and metabolic profiling in db/db mice. Phytomedicine 95:153777PubMedCrossRef
22.
Rojas A, Delgado-López F, González I, Pérez-Castro R, Romero J, Rojas I (2013) The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. Cell Signal 25(3):609–614PubMedCrossRef
23.
Ni WJ, Tang LQ, Zhou H, Ding HH, Qiu YY (2016) Renoprotective effect of berberine via regulating the PGE2 -EP1-Gαq-Ca(2+) signalling pathway in glomerular mesangial cells of diabetic rats. J Cell Mol Med 20(8):1491–1502PubMedPubMedCentralCrossRef
24.
Qiu YY, Tang LQ, Wei W (2017) Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy. Mol Cell Endocrinol 443:89–105PubMedCrossRef
25.
Tang LQ, Liu S, Zhang ST, Zhu LN, Wang FL (2014) Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. Mol Biol Rep 41(5):3339–3347PubMedCrossRef
26.
Guo Y, Ran Z, Zhang Y et al (2020) Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells. Biomed Pharmacother 131:110684PubMedCrossRef
27.
Liu M, Pan Q, Chen Y et al (2015) Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy. Sci Rep 5:11219PubMedPubMedCentralCrossRef
28.
Ma T, Zheng Z, Guo H et al (2019) 4-O-methylhonokiol ameliorates type 2 diabetes-induced nephropathy in mice likely by activation of AMPK-mediated fatty acid oxidation and Nrf2-mediated anti-oxidative stress. Toxicol Appl Pharmacol 370:93–105PubMedCrossRef
29.
Rong Q, Han B, Li Y, Yin H, Li J, Hou Y (2021) Berberine reduces lipid accumulation by promoting fatty acid oxidation in renal tubular epithelial cells of the diabetic kidney. Front Pharmacol 12:729384PubMedCrossRef
30.
Viollet B, Lantier L, Devin-Leclerc J et al (2009) Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed) 14(9):3380–3400PubMedCrossRef
31.
32.
Dugan LL, You YH, Ali SS et al (2013) AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 123(11):4888–4899PubMedPubMedCentralCrossRef
33.
Szrejder M, Piwkowska A (2019) AMPK signalling: implications for podocyte biology in diabetic nephropathy. Biol Cell 111(5):109–120PubMedCrossRef
34.
Gao J, Liu P, Shen Z et al (2021) Morroniside promotes PGC-1α-mediated cholesterol efflux in sodium palmitate or high glucose-induced mouse renal tubular epithelial cells. Biomed Res Int 2021:9942152PubMedPubMedCentralCrossRef
35.
Cheng D, Gao L, Su S et al (2019) Moringa isothiocyanate activates Nrf2: potential role in diabetic nephropathy. AAPS J 21(2):31PubMedCrossRef
36.
Zhang B, Zhang X, Zhang C, Shen Q, Sun G, Sun X (2019) Notoginsenoside R1 Protects db/db mice against diabetic nephropathy via upregulation of Nrf2-mediated HO-1 expression. Molecules 24(2):247PubMedPubMedCentralCrossRef
37.
Zou T, Zhu M, Ma YC et al (2018) MicroRNA-410-5p exacerbates high-fat diet-induced cardiac remodeling in mice in an endocrine fashion. Sci Rep 8(1):8780PubMedPubMedCentralCrossRef
38.
Wang K, Zheng X, Pan Z et al (2020) Icariin prevents extracellular matrix accumulation and ameliorates experimental diabetic kidney disease by inhibiting oxidative stress via GPER mediated p62-dependent Keap1 degradation and Nrf2 activation. Front Cell Dev Biol 8:559PubMedPubMedCentralCrossRef
39.
Gorin Y, Block K (2013) Nox4 and diabetic nephropathy: with a friend like this, who needs enemies. Free Radic Biol Med 61:130–142PubMedCrossRef
40.
Jha JC, Gray SP, Barit D et al (2014) Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 25(6):1237–1254PubMedPubMedCentralCrossRef
41.
Mahimainathan L, Das F, Venkatesan B, Choudhury GG (2006) Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55(7):2115–2125PubMedCrossRef
42.
Yong R, Chen XM, Shen S et al (2013) Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling. PLoS One 8(8):e73428PubMedPubMedCentralCrossRef
43.
Hong JN, Li WW, Wang LL et al (2017) Jiangtang decoction ameliorate diabetic nephropathy through the regulation of PI3K/Akt-mediated NF-κB pathways in KK-Ay mice. Chin Med 12:13PubMedPubMedCentralCrossRef
44.
45.
Chen J, Yang Y, Lv Z et al (2020) Study on the inhibitive effect of Catalpol on diabetic nephropathy. Life Sci 257:118120PubMedCrossRef
46.
Chen J, Hou XF, Wang G et al (2016) Terpene glycoside component from Moutan cortex ameliorates diabetic nephropathy by regulating endoplasmic reticulum stress-related inflammatory responses. J Ethnopharmacol 193:433–444PubMedCrossRef
47.
Zhong Y, Lee K, Deng Y et al (2019) Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun 10(1):4523PubMedPubMedCentralCrossRef
48.
Han W, Ma Q, Liu Y et al (2019) Huangkui capsule alleviates renal tubular epithelial-mesenchymal transition in diabetic nephropathy via inhibiting NLRP3 inflammasome activation and TLR4/NF-κB signaling. Phytomedicine 57:203–214PubMedCrossRef
49.
Hao CM, Breyer MD (2008) Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70:357–377PubMedCrossRef
50.
Zhang T, Zhu Q, Shao Y, Wang K, Wu Y (2017) Paeoniflorin prevents TLR2/4-mediated inflammation in type 2 diabetic nephropathy. Biosci Trends 11(3):308–318PubMedCrossRef
51.
52.
Shao YX, Xu XX, Wang K, Qi XM, Wu YG (2017) Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway. Drug Des Devel Ther 11:3221–3233PubMedPubMedCentralCrossRef
53.
Qi MY, He YH, Cheng Y et al (2021) Icariin ameliorates streptozocin-induced diabetic nephropathy through suppressing the TLR4/NF-κB signal pathway. Food Funct 12(3):1241–1251PubMedCrossRef
54.
Ma L, Wu F, Shao Q, Chen G, Xu L, Lu F (2021) Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway. Drug Des Devel Ther 15:3207–3221PubMedPubMedCentralCrossRef
55.
Qiu YY, Tang LQ (2016) Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res 114:251–264PubMedCrossRef
56.
Shahzad K, Bock F, Dong W et al (2015) Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 87(1):74–84PubMedCrossRef
57.
58.
Lu M, Yin N, Liu W, Cui X, Chen S, Wang E (2017) Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling. Biomed Res Int 2017:1516985PubMedPubMedCentralCrossRef
59.
Wang S, Zhao X, Yang S, Chen B, Shi J (2017) Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway. Chem Biol Interact 278:48–53PubMedCrossRef
60.
Wu D et al (2016) A novel mechanism of action for salidroside to alleviate diabetic albuminuria: effects on albumin transcytosis across glomerular endothelial cells. Am J Physiol Endocrinol Metab 310(3):E225-237PubMedCrossRef
61.
Ribback S et al (2015) PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget 6(15):13036–13048PubMedPubMedCentralCrossRef
62.
Lin W, Liu G, Kang X et al (2021) Ellagic acid inhibits high glucose-induced injury in rat mesangial cells via the PI3K/Akt/FOXO3a signaling pathway. Exp Ther Med 22(3):1017PubMedPubMedCentralCrossRef
63.
Jing D, Bai H, Yin S (2017) Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways. Exp Ther Med 14(5):5163–5169PubMedPubMedCentral
64.
Sun SF, Zhao TT, Zhang HJ et al (2015) Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 42(6):662–670PubMedCrossRef
65.
Zhang NN, Kang JS, Liu SS et al (2020) Flavanomarein inhibits high glucose-stimulated epithelial-mesenchymal transition in HK-2 cells via targeting spleen tyrosine kinase. Sci Rep 10(1):439PubMedPubMedCentralCrossRef
66.
Zhang X, He H, Liang D et al (2016) Protective effects of berberine on renal injury in streptozotocin (STZ)-induced diabetic mice. Int J Mol Sci 17(8):1327PubMedPubMedCentralCrossRef
67.
Chen YCL, Yang T (2021) Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-β/Smad and JAK2/STAT3/SOCS1 pathway. Life Sci 271:119197PubMedCrossRef
68.
Xu XX, Zhang W, Zhang P, Qi XM, Wu YG, Shen JJ (2013) Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats. Phytomedicine 20(10):820–827PubMedCrossRef
69.
Muskiet MH, Smits MM, Morsink LM, Diamant M (2014) The gut-renal axis: do incretin-based agents confer renoprotection in diabetes. Nat Rev Nephrol 10(2):88–103PubMedCrossRef
70.
Ni WJ, Ding HH, Zhou H, Qiu YY, Tang LQ (2015) Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. Eur J Pharmacol 764:448–456PubMedCrossRef
71.
Tu Q, Li Y, Jin J, Jiang X, Ren Y, He Q (2019) Curcumin alleviates diabetic nephropathy via inhibiting podocyte mesenchymal transdifferentiation and inducing autophagy in rats and MPC5 cells. Pharm Biol 57(1):778–786PubMedPubMedCentralCrossRef
72.
Liu W, Liang L, Zhang Q et al (2021) Effects of andrographolide on renal tubulointersticial injury and fibrosis. Evidence of its mechanism of action. Phytomedicine 91:153650PubMedCrossRef
73.
Chen Y, Chen J, Jiang M et al (2020) Loganin and catalpol exert cooperative ameliorating effects on podocyte apoptosis upon diabetic nephropathy by targeting AGEs-RAGE signaling. Life Sci 252:117653PubMedCrossRef
74.
Lei X, Zhang BD, Ren JG, Luo FL (2018) Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway. Life Sci 206:77–83PubMedCrossRef
75.
Lei X, Zhang L, Li Z, Ren J (2018) Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. Drug Des Devel Ther 12:2785–2793PubMedPubMedCentralCrossRef
76.
Tian N, Gao Y, Wang X et al (2018) Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy. Drug Des Devel Ther 12:2195–2211PubMedPubMedCentralCrossRef
77.
Xing L, Fang J, Zhu B et al (2021) Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy. Life Sci 269:119068PubMedCrossRef
78.
Yang S, Deng H, Zhang Q et al (2016) Amelioration of diabetic mouse nephropathy by catalpol correlates with down-regulation of Grb10 expression and activation of insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling. PLoS One 11(3):e0151857PubMedPubMedCentralCrossRef
79.
Yu J, Zong GN, Wu H, Zhang KQ (2019) Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice. Acta Pharmacol Sin 40(12):1544–1554PubMedPubMedCentralCrossRef
80.
Zang Y, Liu S, Cao A et al (2021) Astragaloside IV inhibits palmitic acid-induced apoptosis through regulation of calcium homeostasis in mice podocytes. Mol Biol Rep 48(2):1453–1464PubMedPubMedCentralCrossRef
81.
Chen Y, Liu Q, Shan Z et al (2019) Catalpol ameliorates podocyte injury by stabilizing cytoskeleton and enhancing autophagy in diabetic nephropathy. Front Pharmacol 10:1477PubMedPubMedCentralCrossRef
82.
Su J, Gao C, Xie L et al (2021) Astragaloside II ameliorated podocyte injury and mitochondrial dysfunction in streptozotocin-induced diabetic rats. Front Pharmacol 12:638422PubMedPubMedCentralCrossRef
83.
Wu F, Li S, Zhang N et al (2018) Hispidulin alleviates high-glucose-induced podocyte injury by regulating protective autophagy. Biomed Pharmacother 104:307–314PubMedCrossRef
84.
Guo H, Wang Y, Zhang X et al (2017) Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy. Sci Rep 7(1):6852PubMedPubMedCentralCrossRef
85.
Wang X, Gao Y, Tian N et al (2019) Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis. Sci Rep 9(1):323PubMedPubMedCentralCrossRef
86.
87.
Qin X, Jiang M, Zhao Y et al (2020) Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis. Br J Pharmacol 177(16):3646–3661PubMedPubMedCentralCrossRef
88.
Xu J, Liu L, Gan L et al (2021) Berberine acts on C/EBPβ/lncRNA Gas5/miR-18a-5p loop to decrease the mitochondrial ROS generation in HK-2 cells. Front Endocrinol (Lausanne) 12:675834PubMedCrossRef
89.
Qin X, Zhao Y, Gong J et al (2019) Berberine protects glomerular podocytes via inhibiting Drp1-mediated mitochondrial fission and dysfunction. Theranostics 9(6):1698–1713PubMedPubMedCentralCrossRef
90.
Xue H, Li P, Luo Y et al (2019) Salidroside stimulates the Sirt1/PGC-1α axis and ameliorates diabetic nephropathy in mice. Phytomedicine 54:240–247PubMedCrossRef
91.
Zhang T, Chi Y, Kang Y et al (2019) Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α mediated attenuation of mitochondrial oxidative stress. J Cell Physiol 234(4):5033–5043PubMedCrossRef
92.
Jia Z, Wang K, Zhang Y et al (2021) Icariin ameliorates diabetic renal tubulointerstitial fibrosis by restoring autophagy via regulation of the miR-192-5p/GLP-1R pathway. Front Pharmacol 12:720387PubMedPubMedCentralCrossRef
93.
Zang L et al (2022) Icariin inhibits epithelial mesenchymal transition of renal tubular epithelial cells via regulating the miR-122-5p/FOXP2 axis in diabetic nephropathy rats. J Pharmacol Sci 148(2):204–213PubMedCrossRef
94.
Ding X, Zhao H, Qiao C (2022) Icariin protects podocytes from NLRP3 activation by Sesn2-induced mitophagy through the Keap1-Nrf2/HO-1 axis in diabetic nephropathy. Phytomedicine 99:154005PubMedCrossRef
95.
Qiao C, Ye W, Li S, Wang H, Ding X (2018) Icariin modulates mitochondrial function and apoptosis in high glucose-induced glomerular podocytes through G protein-coupled estrogen receptors. Mol Cell Endocrinol 473:146–155PubMedCrossRef
96.
AlTamimi JZ, AlFaris NA, Al-Farga AM, Alshammari GM, BinMowyna MN, Yahya MA (2021) Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKCβ/p66Shc axis and activation of FOXO-3a. J Nutr Biochem 87:108515PubMedCrossRef
97.
Ghasemi H, Einollahi B, Kheiripour N, Hosseini-Zijoud SR, Farhadian NM (2019) Protective effects of curcumin on diabetic nephropathy via attenuation of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) expression and alleviation of oxidative stress in rats with type 1 diabetes. Iran J Basic Med Sci 22(4):376–383PubMedPubMedCentral
98.
Lu Z, Zhong Y, Liu W, Xiang L, Deng Y (2019) The efficacy and mechanism of chinese herbal medicine on diabetic kidney disease. J Diabetes Res 2019:2697672PubMedPubMedCentralCrossRef
99.
Memarzia A, Khazdair MR, Behrouz S et al (2021) Experimental and clinical reports on anti-inflammatory, antioxidant, and immunomodulatory effects of Curcuma longa and curcumin, an updated and comprehensive review. BioFactors 47(3):311–350PubMedCrossRef
100.
Jie Z, Chao M, Jun A, Wei S, LiFeng M (2021) Effect of curcumin on diabetic kidney disease: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Evid Based Complement Alternat Med 2021:6109406PubMedPubMedCentral
101.
Jiménez-Osorio AS, García-Niño WR, González-Reyes S et al (2016) The Effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr 26(4):237–244PubMedCrossRef
102.
de Oliveira MR, Nabavi SF, Habtemariam S, Erdogan Orhan I, Daglia M, Nabavi SM (2015) The effects of baicalein and baicalin on mitochondrial function and dynamics: a review. Pharmacol Res 100:296–308PubMedCrossRef
103.
Yingrui W, Zheng L, Guoyan L, Hongjie W (2022) Research progress of active ingredients of Scutellaria baicalensis in the treatment of type 2 diabetes and its complications. Biomed Pharmacother 148:112690PubMedCrossRef
104.
Yang M, Kan L, Wu L, Zhu Y, Wang Q (2019) Effect of baicalin on renal function in patients with diabetic nephropathy and its therapeutic mechanism. Exp Ther Med 17(3):2071–2076PubMedPubMedCentral
105.
Derosa G, Maffioli P, Sahebkar A (2016) Ellagic acid and its role in chronic diseases. Adv Exp Med Biol 928:473–479PubMedCrossRef
106.
Ghadimi M, Foroughi F, Hashemipour S et al (2021) Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes. Phytother Res 35(2):1023–1032PubMedCrossRef
107.
Cicero AF, Baggioni A (2016) Berberine and its role in chronic disease. Adv Exp Med Biol 928:27–45PubMedCrossRef
108.
Yao JM SXL, Wang HJ ZJY, Shang HX LL et al (2015) Efficacy and safety of berberine in treatment of diabetic nephropathy: a meta analysis. Chin J Clin 9(23):4396–4402
109.
Ni WJ, Ding HH, Tang LQ (2015) Berberine as a promising anti-diabetic nephropathy drug: an analysis of its effects and mechanisms. Eur J Pharmacol 760:103–112PubMedCrossRef
110.
111.
Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR, Shams M (2019) Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab 45(1):53–59PubMedCrossRef
112.
Panossian A, Wikman G, Sarris J (2010) Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 17(7):481–493PubMedCrossRef
113.
Ganzera M, Yayla Y, Khan IA (2001) Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatography. Chem Pharm Bull (Tokyo) 49(4):465–467PubMedCrossRef
114.
Yuan LXL (2018) Evaluation on the effect of rhodiola sachalinensis on the improvement of early diabetic nephropathy. Chin Commun Doct 34(5):103–105
115.
Fallahzadeh MK, Dormanesh B, Sagheb MM et al (2012) Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 60(6):896–903PubMedCrossRef
116.
Voroneanu L, Siriopol D, Dumea R et al (2017) Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial. Int Urol Nephrol 49(12):2195–2204PubMedCrossRef
117.
Zhou YX, Zhang H, Peng C (2014) Puerarin: a review of pharmacological effects. Phytother Res 28(7):961–975PubMedCrossRef
118.
Bin Wang SC, Xiufeng Yan ML, Daqi Li PL, Ti G (2015) The therapeutic effect and possible harm of puerarin for treatment of stage III diabetic nephropathy: a meta-analysis. Altern Ther Health Med 21(1):36–44PubMed
119.
Liu X, Yao L, Sun D et al (2016) Effect of breviscapine injection on clinical parameters in diabetic nephropathy: a meta-analysis of randomized controlled trials. Exp Ther Med 12(3):1383–1397PubMedPubMedCentralCrossRef
120.
121.
Zhu LB (2009) Effect of fluvastatin and emodin on TGF-b1 level in patients. Heilongjiang J Tradit Chin Med 38:52–53
Metadaten
Titel
Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease
verfasst von
Xuexun Chen
Xuan Li
Bo Cao
Xinping Chen
Kexin Zhang
Fang Han
Chengxia Kan
Jingwen Zhang
Xiaodong Sun
Zhentao Guo
Publikationsdatum
08.08.2023
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 2/2024
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03703-0

Weitere Artikel der Ausgabe 2/2024

Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis

  • Open Access
  • Urology - Original Paper

Cardiorenal syndrome and iron supplementation—more benefits than risks: a narrative review

  • Nephrology - Review

Prevalence and associated factors of frailty in patients with chronic kidney disease: a cross-sectional analysis of PEAKING study

  • Open Access
  • Nephrology - Original Paper

Efficacy of low-intensity shockwave therapy with different tadalafil regimens in patients with PDE5 inhibitor-resistant erectile dysfunction: a retrospective cohort study

  • Urology - Original Paper

Reduction in NGAL at 48 h predicts the progression to CKD in patients with septic associated AKI: a single-center clinical study

  • Nephrology - Original Paper

Red blood cell distribution width as a biomarker in acute kidney injury: too soon?

  • Nephrology - Letter to the Editor

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise